Modeling Skeletal Muscle Laminopathies Using Human Induced Pluripotent Stem Cells Carrying Pathogenic LMNA Mutations

Laminopathies are a clinically heterogeneous group of disorders caused by mutations in . The main proteins encoded by are Lamin A and C, which together with Lamin B1 and B2, form the nuclear lamina: a mesh-like structure located underneath the inner nuclear membrane. Laminopathies show striking tiss...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in physiology Vol. 9; p. 1332
Main Authors Steele-Stallard, Heather B, Pinton, Luca, Sarcar, Shilpita, Ozdemir, Tanel, Maffioletti, Sara M, Zammit, Peter S, Tedesco, Francesco Saverio
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 15.10.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Laminopathies are a clinically heterogeneous group of disorders caused by mutations in . The main proteins encoded by are Lamin A and C, which together with Lamin B1 and B2, form the nuclear lamina: a mesh-like structure located underneath the inner nuclear membrane. Laminopathies show striking tissue specificity, with subtypes affecting striated muscle, peripheral nerve, and adipose tissue, while others cause multisystem disease with accelerated aging. Although several pathogenic mechanisms have been proposed, the exact pathophysiology of laminopathies remains unclear, compounded by the rarity of these disorders and lack of easily accessible cell types to study. To overcome this limitation, we used induced pluripotent stem cells (iPSCs) from patients with skeletal muscle laminopathies such as -related congenital muscular dystrophy and limb-girdle muscular dystrophy 1B, to model disease phenotypes . iPSCs can be derived from readily accessible cell types, have unlimited proliferation potential and can be differentiated into cell types that would otherwise be difficult and invasive to obtain. iPSC lines from three skeletal muscle laminopathy patients were differentiated into inducible myogenic cells and myotubes. Disease-associated phenotypes were observed in these cells, including abnormal nuclear shape and mislocalization of nuclear lamina proteins. Nuclear abnormalities were less pronounced in monolayer cultures of terminally differentiated skeletal myotubes than in proliferating myogenic cells. Notably, skeletal myogenic differentiation of -mutant iPSCs in artificial muscle constructs improved detection of myonuclear abnormalities compared to conventional monolayer cultures across multiple pathogenic genotypes, providing a high-fidelity modeling platform for skeletal muscle laminopathies. Our results lay the foundation for future iPSC-based therapy development and screening platforms for skeletal muscle laminopathies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Vincent Gache, INSERM U1217 Institut NeuroMyoGène (INMG), France; Sue Shackleton, University of Leicester, United Kingdom
Present Address: Sara M. Maffioletti, San Raffaele Telethon Institute for Gene Therapy (TIGET), San Raffaele Scientific Institute, Milan, Italy
Edited by: Julien Ochala, King's College London, United Kingdom
These authors share joint senior authorship
This article was submitted to Striated Muscle Physiology, a section of the journal Frontiers in Physiology
ISSN:1664-042X
1664-042X
DOI:10.3389/fphys.2018.01332